| Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More | Frank Vinluan | 10/09/20 | National |
| In RNAi Move, Takeda Fronts $300M to Team Up on Arrowhead Liver Drug | Frank Vinluan | 10/08/20 | National |
| Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More | Frank Vinluan | 09/18/20 | National |
| Reeling From FDA Rejection, Intercept Pharma Slashes Headcount by 25% | Frank Vinluan | 09/01/20 | New York |
| Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More | Frank Vinluan | 08/28/20 | National |
| Gilead Sciences Splashes Out $300M for Tizona Stake & Option to Acquire | Sarah de Crescenzo | 07/21/20 | San Francisco |
| Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More | Frank Vinluan | 07/17/20 | National |
| Amgen Doubles Down on BeiGene Collaboration, Investing $421M More | Sarah de Crescenzo | 07/13/20 | San Francisco |
| Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better | Frank Vinluan | 06/19/20 | Raleigh Durham |
| Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More | Frank Vinluan | 06/05/20 | National |
| Variant Emerges With $16M to Find “Outlier Humans” to Reveal New Drugs | Sarah de Crescenzo | 05/28/20 | Seattle |
| BCMA Delay: FDA Refuses Review of Bristol Drug, Asks for More Info | Frank Vinluan | 05/13/20 | New York |
| QurAlis Hauls In $42M to Move New ALS Therapies Into Human Testing | Sarah de Crescenzo | 05/13/20 | Boston |
| Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More | Sarah de Crescenzo | 04/17/20 | National |
| Akero Heads to Top of Class in NASH; Genfit Says Pandemic Won’t Delay Data | Joseph Haas | 04/10/20 | National |
| Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More | Sarah de Crescenzo | 04/03/20 | National |
| Fears Of Recession Mount As Coronavirus Declared A Pandemic | Andrew McConaghie | 03/19/20 | National |
| Takeda Bases PvP Biologics Buyout on Promising Early Celiac Drug Data | Sarah de Crescenzo | 02/26/20 | San Diego |
| Esperion’s FDA-Approved Cholesterol Drug Priced Even Lower Than Expected | Frank Vinluan | 02/24/20 | Detroit Ann Arbor |
| Lundbeck’s Alder Bio Bet Pays Off With FDA Approval of Migraine Drug | Frank Vinluan | 02/23/20 | National |
| Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer | Frank Vinluan | 02/12/20 | San Francisco |
| Mirati Adds Execs With Commercial Experience at Spark, Bristol-Myers | Sarah de Crescenzo | 01/08/20 | San Diego |
| Merck Ramps Up KRAS Chase Through Licensing Deal With Taiho, Astex | Frank Vinluan | 01/06/20 | New York |
| Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines | Sarah de Crescenzo | 12/24/19 | National |
| Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning | Frank Vinluan | 12/12/19 | National |
| Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B | Frank Vinluan | 11/25/19 | New York |
| Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More | Frank Vinluan | 11/22/19 | National |
| AstraZeneca Chooses China for R&D and AI Centers, $1B Biotech Fund | Gareth Macdonald | 11/06/19 | National |
| Biotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & More | Frank Vinluan | 11/01/19 | National |
| Led by Gilead Veteran Riva, Glenmark’s Ichnos Steps Out on Its Own | Sarah de Crescenzo | 10/15/19 | New York |
